Zoetis (ZTS) Given a $80.00 Price Target by Cantor Fitzgerald Analysts
Several other research analysts also recently issued reports on ZTS. Cowen set a $70.00 target price on shares of Zoetis and gave the stock a buy rating in a research note on Thursday, August 24th. Piper Jaffray Companies set a $73.00 target price on shares of Zoetis and gave the stock a buy rating in a research note on Friday, August 25th. Stifel Nicolaus reiterated a buy rating and issued a $65.00 target price on shares of Zoetis in a research note on Friday, September 1st. BidaskClub upgraded shares of Zoetis from a buy rating to a strong-buy rating in a research note on Tuesday, September 12th. Finally, Zacks Investment Research upgraded shares of Zoetis from a hold rating to a buy rating and set a $71.00 target price on the stock in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company. Zoetis presently has a consensus rating of Buy and an average target price of $68.53.
Shares of Zoetis (NYSE:ZTS) opened at $72.23 on Tuesday. The firm has a market cap of $34,972.68, a PE ratio of 32.92, a price-to-earnings-growth ratio of 2.15 and a beta of 1.06. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45. Zoetis has a fifty-two week low of $50.57 and a fifty-two week high of $72.79.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be given a dividend of $0.126 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.70%. Zoetis’s dividend payout ratio is 22.11%.
A number of institutional investors have recently modified their holdings of the stock. AXA lifted its position in Zoetis by 15.2% during the third quarter. AXA now owns 252,241 shares of the company’s stock valued at $16,083,000 after purchasing an additional 33,227 shares during the period. Steward Partners Investment Advisory LLC bought a new position in Zoetis during the third quarter valued at approximately $114,000. Garde Capital Inc. bought a new position in Zoetis during the third quarter valued at approximately $419,000. Cetera Advisors LLC bought a new position in Zoetis during the third quarter valued at approximately $211,000. Finally, Yellowstone Partners LLC bought a new position in Zoetis during the third quarter valued at approximately $694,000. Institutional investors own 93.33% of the company’s stock.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.